PDS Biotechnology Corporation

PDSBNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

55.9M

on 2026-06-30, from 36.7M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$200.0M

S-3 of 2025-08-29. 1 prospectus supplement filed under it since. S-3 ↗

$50.0M

Yorkville Securities, agreement of 2026-06-15. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

The 10-Q filed 2026-08-13 is not read yet.

Cash

1.3 quarters

$5.6M on 2026-06-30 ÷ $4.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-11-12	Public offering incl. 0.06M pre-funded	5,800,000	$0.91	$5.3M	424B5 ↗
2025-02-28	Public offering incl. 0.93M pre-funded	7,330,121	$1.50	$10.9M	424B5 ↗
2025-02-26	Private placement incl. 0.93M pre-funded	1,866,668	not read	$11.0M	8-K ↗

Also on file: $6.0M convertible notes, 2024-08-13 8-K ↗ · $22.2M convertible notes, 2025-04-30 8-K ↗ · $6.0M convertible notes, 2026-06-15 8-K ↗